Two South Korean conglomerates – Samyang Holdings Corp. and Samsung Biologics Co. Ltd. – listed their newly spun-off biopharmaceutical units on Korea Exchange’s (KRX) main trading board Nov. 24.
Biopharmas raising money in public or private financings, including: Algernon, Annexon, Artios, Bambusa, Captain T Cell, Imbria, Inventiva, Mitorx, Nextcure.
DNA damage response specialist Artios Ltd. has closed an oversubscribed $115 million series D after delivering positive phase I/IIa data for its two lead programs.
Fresh cash infusions are on the way for European biotech after two leading venture capital firms announced large new funds. Asset-focused Medicxi has closed an oversubscribed €500 million (US$580 million) fund, while Sofinnova Partners exceeded its target of €500 million to close its Capital XI fund at €650 million (US$753.5 million).
RSS
